N-acetylcysteine replenishes glutathione in HIV infection

European Journal of Clinical Investigation

Volumn 30, Issue 10, 2000, Pages 915-929

  De Rosa, S C ^a,i   Zaretsky, M D ^b   Dubs, J G ^a   Roederer, M ^c   Anderson, M ^d   Green, A ^a   Mitra, D ^e   Watanabe, N ^f   Nakamura, H ^g   Tjioe, I ^a   Deresinski, S C ^h   Moore, W A ^a   Ela, S W ^a   Parks, D ^a   Herzenberg, L A ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Department of Pharmacology and Toxicology and Mass Spectrometry Core Facility   (United States)

^e Medical Institute   (India)

^f UNIVERSITY OF TOKYO   (Japan)

^g KYOTO UNIVERSITY   (Japan)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

Author keywords

Glutathione; GSH; GSH deficiency; HIV; N acetylcysteine; NAC

Indexed keywords

ACETYLCYSTEINE; BETA 2 MICROGLOBULIN; GLUTATHIONE; PARACETAMOL; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GLUTATHIONE METABOLISM; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LIVER CIRRHOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; OLIGOPHRENIA; OPPORTUNISTIC INFECTION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; T LYMPHOCYTE;

ACETYLCYSTEINE; ADULT; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; GLUTATHIONE; HIV INFECTIONS; HUMANS; MALE; SURVIVAL ANALYSIS;

EID: 0033788034     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00736.x     Document Type: Article

References (99)

1. Intracellular thiols regulate activation of nuclear factor kappaB and transcription of human immunodeficiency virus
2. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappaB transcription factor and HIV-1
3. Glutathione ascorbic acid antioxidant system in animals
4. Glutathione-dependent protection against oxidative injury
5. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the National Multicenter Study 1976-85
6. Paracetamol (acetaminophen) poisoning
7. Glutathione: Metabolism and physiological functions
8. Glutathione. Chemical, Biochemical, and Medical Aspects
9. De novo synthesis of glutathione is required for both entry into and progression through the cell cycle
10. Immunologic NO synthase: Elevations in severe AIDS dementia and induction by HIV-1 gp41
11. HIV-induced cysteine deficiency and T-cell dysfunction - A rationale for treatment with N-acetylcysteine
12. Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2
13. Regulation by glutathione of the activation and differentiation of IL-4-dependent activated killer cells
14. Thiol-mediated redox regulation of lymphocyte proliferation. Possible involvement of adult T cell leukemia-derived factor and glutathione in transferrin receptor expression
15. Glutathione increases interleukin-2 production in human lymphocytes
16. Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis
17. Possible availability of N-acetylcysteine as an adjunct to cytokine therapy for hepatocellular carcinoma
18. N-acetylcysteine improves cytotoxic activity of cirrhotic rat liver-associated mononuclear cells
19. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns
20. Oxidative stress and the pathogenesis of Parkinson's disease
21. Neurodegenerative disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death
22. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease
23. Increased cerebrospinal fluid and plasma levels of ultra-weak chemiluminescence are associated with changes in the thiol pool and lipid-soluble fluorescence in multiple sclerosis: The pathogenic role of oxidative stress
24. Understanding cell death in Parkinson's disease
25. Glutathione deficiency in human disease
26. Glutathione, oxidative stress and aging
27. Glutathione kinetics in normal man and in patients with liver cirrhosis
28. Vagal system impairment in human immunodeficiency virus-positive patients with chronic hepatitis C: Does hepatic glutathione deficiency have a pathogenetic role?
29. Plasma nitrite/nitrate and total thiols as markers of nitric oxide production and oxidative stress in patients with chronic obstructive pulmonary disease and chronic respiratory insufficiency
30. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine
31. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients
32. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals
33. Glutathione depletion in HIV-infected patients: Role of cysteine deficiency and effect of oral N-acetylcysteine
34. Decreased release of glutathione into the systemic circulation of patients with HIV infection
35. Resistance of chimpanzee T cells to human immunodeficiency virus type 1 Tat-enhanced oxidative stress and apoptosis
36. Alveolar fluid glutathione decreases in asymptomatic HIV-seropositive subjects over time
37. Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: Toxicological and pathological implications
38. The role of oxidative imbalance in progression to AIDS. Effect of the thiol supplier N-acetylcysteine
39. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active anti-retroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure
40. Erythrocyte glutathione deficiency in symptom-free HIV infection is associated with decreased synthesis rate
41. Low serum thiol levels predict shorter times-to-death among HIV-infected injecting drug users
42. CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses
43. Intracellular glutathione levels in T cell subsets decrease in HIV infected individuals
44. Glutathione deficiency and human immunodeficiency virus infection
45. Glutathione deficiency is associated with impaired survival in HIV disease
46. Glutathione therapy: From prodrugs to genes
47. Mechanism of action of paracetamol protective agents in mice in vivo
48. Dose-dependent pharmacokinetics of acetaminophen: Evidence of glutathione depletion in humans
49. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: A critical review
50. Antiproliferative agents drugs used for immunosuppression
51. Cysteine and glutathione deficiency in AIDS patients - A rationale for the treatment with N-AcetylCysteine
52. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine
53. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine
54. Inhibition of HIV-1 replication and NF-kappaB activity by cysteine and cysteine derivatives
55. GSH rescue by N-acetylcysteine
56. Effect of N-acetylcysteine (NAC) treatment on HIV-1 infection: A double-blind placebo-controlled trial
57. Glutathione measurement on the flow cytometer
58. Glutathione homeostasis is disturbed in CD4-positive lymphocytes of HIV-seropositive individuals
59. Markedly disturbed glutathione redox status in CD45RA+CD4+ lymphocytes in human immunodeficiency virus type 1 infection is associated with selective depletion of this lymphocyte subset
60. Determination of glutathione and glutathione disulfide in biological samples
61. An improved monobromobimane assay for glutathione utilizing tris-(2-carboxyethyl) phosphine as the reductant
62. Disregulation of leukocyte glutathione in AIDS
63. Tour guide of statistical analysis
64. Estimation of missing values
65. Clinical pharmacokinetics of N-acetylcysteine
66. Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection: Effect of parenteral treatment with SAMe
67. Glutathione concentrations in plasma and blood are markedly decreased in HIV-infected children
68. L-2-oxothiazolidine-4-carboxylic acid and glutathione in human immunodeficiency virus
69. The safety, pharmacokinetics, and antiviral activity of N-acetylcysteine in HIV-infected individuals
70. The safety, pharmacokinetics, and antiviral activity of N-acetylcysteine in HIV-infected individuals
71. Safety, pharmacokinetics and antiviral activity of N-acetylcysteine in HIV-infected individuals
72. Supplementation of N-acetylcysteine fails to increase glutathione in lymphocytes and plasma of patients with AIDS
73. Lack of short-term efficacy of N-acetyl-L-cysteine in human immunodeficiency virus-positive patients with CD4 cell counts <250/ mm (3)
74. Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-I-infected patients: A randomized, controlled pilot study
75. Glutathione measurement in human plasma Evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC
76. Massive loss of sulfur in HIV infection
77. Improvement of immune functions in HIV infection by sulfur supplementation: Two randomized trials
78. Human immunodeficiency virus type 1 tat upregulates interleukin-2 secretion in activated T cells
79. HIV-1 Tat potentiates TNF-induced NF-kappaB activation and cytotoxicity by altering the cellular redox state
80. Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice
81. Abnormalities in the metabolism of acetaminophen in patients infected with the human immunodeficiency virus (HIV)
82. Antioxidant status in patients with acute respiratory distress syndrome
83. Plasma levels of glutathione, alpha-tocopherol and lipid peroxides in polytraumatized patients; evidence for a stimulating effect of TNF alpha on glutathione synthesis
84. Identification of glutathione S-transferase isozymes and gamma-glutamylcysteine synthetase as negative acute-phase proteins in rat liver
85. Treatment with glutathione precursor decreases cytokine activity
86. Low whole blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, elevated liver enzymes, low platelets syndrome
87. Increased oxidative stress in dilated cardiomyopathic heart failure
88. Evidence for the role of an altered redox state in hyporesponsiveness of synovial T cells in rheumatoid arthritis
89. Review of oxidative stress in brain and spinal cord injury: Suggestions for pharmacological and nutritional management strategies
90. Age and gender dependent levels of glutathione and glutathione S-transferases in human lymphocytes
91. Xenobiotic metabolism, oxidant stress and chronic pancreatitis - Focus on glutathione
92. Glutathione in human plasma: Decline in association with aging, age-related macular degeneration, and diabetes
93. Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes
94. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents